Background:
HIV infection is now a chronic disease due to the availability of antiretroviral therapy (ART) which suppresses plasma viral loads to below the limit of detection and prevents AIDS. However, the virus establishes latency and persists, a clear barrier to curing HIV. Interruption of ART causes viral rebound and thus requires a lifetime of medication for these individuals. We have previously demonstrated that the humanized DRAGA (hDRAGA) mouse (HLA-A2.HLA-DR4.RAG1 KO.IL-2RγcKO.NOD) generated by engrafting CD34+ hematopoietic stem cells from human cord blood is a suitable model to study HIV infection. Subsequently, we evaluated if this mouse could also serve as a model for HIV cure and latency studies. We examined the effects of NU611 in HIV infected hDRAGA mice on viral rebound following ART interruption (ATI). NU611 is a compound that boosts the expression of APOBEC3G, a human antiviral protein that decreases virion infectivity in cells.
Methods:
Humanized DRAGA mice (n=11) were intravaginally infected with HIV. Three weeks post-infection the standard 3-drug regimen: TDF, FTC, DTG in chow was administered for 6-10 weeks and then removed for observation of viral rebound. One week prior to ATI, 6 mice were administered NU611 intraperitoneally weekly and plasma viral loads were monitored by qRT-PCR. The tissues were also evaluated for viral RNA and DNA. Cellular profiles examining any changes in the human immune cells in the blood were performed using flow cytometry. Statistics were performed using Mann-Whitney analyses.
Results:
The plasma viral load decreased within a week of ART administration to below the limit of detection (700 copies/mL) within 5 weeks and remained suppressed while on ART for up to 10 weeks with no viral blips. Following ATI, the viral rebound in all 5 control mice was either higher than or similar to levels before ART administration. In mice treated with NU611, although viral rebound was observed in the plasma 2 weeks post ATI, plasma viral set points were 1 log lower in 5/6 treated mice compared to 5/5 untreated control mice.
Conclusions:
These results demonstrate the persistence of a viral reservoir in this model and the suitability of an APOBEC3G booster to contribute to the control of viral replication. The hDRAGA mice recapitulate some key aspects of HIV remission and rebound following ATI. This knowledge is important as it establishes the hDRAGA mouse as a model for HIV latency and can be utilized to investigate potential therapeutics for HIV cure.